Lyell Immunopharma (LYEL) Accounts Payables (2020 - 2026)

Lyell Immunopharma's Accounts Payables history runs 7 years deep, the most recent figure standing at $5.5 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 46.67% year-over-year to $5.5 million; the TTM figure through Mar 2026 stood at $5.5 million (up 46.67% YoY), while the FY2025 annual figure was $2.9 million, down 46.09% from the prior year.
• Accounts Payables came in at $5.5 million for Q1 2026 at Lyell Immunopharma, up from $2.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $6.5 million in Q1 2022 to a low of $2.6 million in Q3 2025.
• A 5-year average of $4.5 million and a median of $4.4 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables plunged 46.09% in 2025 and surged 46.67% in 2026, its largest moves.
• Lyell Immunopharma's Accounts Payables stood at $3.9 million in 2022, then increased by 22.98% to $4.8 million in 2023, then climbed by 11.4% to $5.4 million in 2024, then slumped by 46.09% to $2.9 million in 2025, then jumped by 89.01% to $5.5 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $5.5 million, $2.9 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison